Overview

Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder

Status:
Completed

Trial end date:
2011-10-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine whether aripiprazole provides additional clinical benefit to patients with Bipolar I disorder when combined with lithium or valproate over 12 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Collaborator:

Otsuka America Pharmaceutical

Treatments:

Aripiprazole
Lithium Carbonate
Valproic Acid